Загрузка видео...

Не удалось загрузить видео

На главную

Dr. Sabine Hazan, speaking at the Cancer Schmancer conference, emphasized that science is on the verge of linking every cancer to specific microbes. She referenced how HPV is associated with cervical cancer, Epstein-Barr with Burkitt's lymphoma, and H. pylori with gastric cancer. Dr. Hazan predicted that, in time, researchers...

29,059 просмотров • 10 месяцев назад •via X (Twitter)

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Dr. Sabine Hazan just issued a chilling warning about the explosion of cancers in young people — and she believes the gut microbiome is the missing link. Colon cancer at 18? Pancreatic cancer in young adults? Breast cancer rates surging since the 80s? She says something is fundamentally changing in humanity — and it's not just better diagnosis. Key points from the clip: - Colon cancer guidelines dropped from age 50 to 45 screenings because cases are appearing so much younger (she's seen an 18-year-old with it). - Rectal bleeding in a young person should trigger colonoscopy — anything less is malpractice in her view. - She suspects we're killing beneficial gut microbes (allowing harmful ones to dominate), creating an environment where cancers thrive. - Known links already exist: Epstein-Barr → Burkitt's lymphoma, HPV → cervical cancer, H. pylori → gastric cancer. - Her lab is now testing pancreatic cancer patients' stools for free ( to hunt for microbiome signals that could enable earlier detection. Her bold theory: In the future, we may discover all cancers are microbiome-related — or triggered by specific microbes. This is not fringe speculation from a researcher who has been sounding alarms on microbiome disruption for years. Are rising young-onset cancers a wake-up call about gut health — or something else entirely? If you or someone you know has pancreatic cancer, she’s offering free stool testing to search for signals.

Camus

49,420 просмотров • 5 месяцев назад

After a year of intensive research, Dr. William Makis presents the most crucial graph of his career: the ivermectin dosing schedule for cancer. Dr. Makis recommends a starting dose of 1mg per kg of body weight per day for most cancers, including breast, colon, lung, pancreatic, renal, gastric, and leukemias. For a 60kg individual, this translates to 60mg daily, which can be taken as: - Five 12mg pills - Or 6ml of liquid (approximately one teaspoon plus 1ml) The evidence supporting the efficacy of ivermectin is compelling and dose-dependent. - Dr. Shankara Chetty observed a significant drop in a prostate cancer patient’s PSA from 89 to 11 after taking 45mg/day. - Dr. Tess Lawry’s case study showed a remarkable decrease in CA125 (an ovarian cancer marker) from 288 to 22 after just 0.2mg/kg. - A long-term Castro study on children with leukemia demonstrated no side effects after 6 months at a dose of 1mg/kg. For aggressive cancers like pancreatic and brain cancers, a higher dose may be necessary due to the blood-brain barrier. Dr. Makis cites examples: - Dr. Landrito’s colleague with terminal gallbladder cancer experienced the disappearance of cancer after 14 months at a dose of 2mg/kg/day. - The highest documented dose is 2.5mg/kg, as reported by Dr. Chetty, with only transient visual side effects that resolved. Mainstream oncology is unlikely to offer this treatment due to ivermectin’s generic, off-patent status and unprofitable nature. Consequently, there are no funded clinical trials. Dr. Makis concludes that using ivermectin in cancer treatment is straightforward and highly safe. He strongly suggests that those struggling with cancer should start with a dose of 1mg/kg/day. This can be taken for several months, even over a year, with an excellent safety profile based on long-term anecdotal evidence. The power to fight cancer may already be within your reach.

Commentary | Global Ivermectin Research Hub

102,157 просмотров • 4 месяцев назад

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Joe Tippens

46,807 просмотров • 1 месяц назад